Table 2 Baseline assessments of the study participants
Triamcinolone acetonide | 10 mg (n = 42) | 40 mg (n = 42) | p-value |
|---|---|---|---|
Pain VAS, Mean ± SD | 5.2 ± 2.4 | 4.9 ± 2.7 | 0.6 |
Global VAS, Mean ± SD | 4.0 ± 2.8 | 4.0 ± 3.1 | 0.9 |
Thai WOMAC score, Mean ± SD | |||
Pain | 4.9 ± 2.1 | 4.7 ± 2.5 | 0.7 |
Stiffness | 3.4 ± 2.9 | 3.0 ± 2.7 | 0.4 |
Use | 3.7 ± 2.5 | 3.7 ± 2.4 | 0.9 |
Total | 4.0 ± 2.1 | 3.8 ± 2.2 | 0.6 |
EQ5D, Mean ± SD | |||
Utility | 0.8 ± 0.2 | 0.8 ± 0.2 | 0.7 |
Health | 73.6 ± 14.4 | 70.2 ± 15.5 | 0.3 |
Thai KOOS, Mean ± SD | |||
Pain | 54.1 ± 17.5 | 60.8 ± 19.3 | 0.1 |
Symptom | 58.4 ± 19.3 | 64.5 ± 19.4 | 0.2 |
Activities of daily living | 56.3 ± 19.4 | 61.6 ± 20.2 | 0.2 |
Sports/recreation | 23.0 ± 21.2 | 28.8 ± 23.0 | 0.3 |
Quality of life | 35.3 ± 17.6 | 35.2 ± 16.4 | 1.0 |
Chair stand test, Mean ± SD | 6.2 ± 4.3 | 6.5 ± 3.6 | 0.7 |
20-m walk, Mean ± SD | 53.5 ± 55.5 | 41.9 ± 48.1 | 0.3 |